Title: Incorporation of pazopanib in maintenance therapy of ovarian cancer
Authors: du Bois, Andreas ×
Floquet, Anne
Kim, Jae-Weon
Rau, Joern
Del Campo, Josep M
Friedlander, Michael
Pignata, Sandro
Fujiwara, Keiichi
Vergote, Ignace
Colombo, Nicoletta
Mirza, Mansoor R
Monk, Bradley J
Kimmig, Rainer
Ray-Coquard, Isabelle
Zang, Rongyu
Diaz-Padilla, Ivan
Baumann, Klaus H
Mouret-Reynier, Marie-Ange
Kim, Jae-Hoon
Kurzeder, Christian
Lesoin, Anne
Vasey, Paul
Marth, Christian
Canzler, Ulrich
Scambia, Giovanni
Shimada, Muneaki
Calvert, Paula
Pujade-Lauraine, Eric
Kim, Byoung-Gie
Herzog, Thomas J
Mitrica, Ionel
Schade-Brittinger, Carmen
Wang, Qiong
Crescenzo, Rocco
Harter, Philipp #
Issue Date: Oct-2014
Publisher: Grune & Stratton
Series Title: Journal of Clinical Oncology vol:32 issue:30 pages:3374-82
Article number: 10.1200/JCO.2014.55.7348
Abstract: Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. Preclinical and clinical studies support VEGFR and PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role of pazopanib maintenance therapy in patients with ovarian cancer whose disease did not progress during first-line chemotherapy.
ISSN: 0732-183X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science